Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

57%

4 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4

3(42.9%)

Phase 1

3(42.9%)

Phase 3

1(14.3%)

7Total

Phase 4(3)

Phase 1(3)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT04045678Phase 1Completed

A Multiple Ascending Dose Study With LY03003 in Patients With Early-stage Parkinson's Disease

Role: collaborator

NCT04044547Phase 1Completed

A Study of LY03003 in Patients With Early-stage Parkinson's Disease

Role: collaborator

NCT01935453Phase 1Completed

A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus to Treat Cancer

Role: collaborator

NCT02319603Phase 4Unknown

To Evaluate the Efficacy and Safety of Wenxin Keli in Treating Atrial Premature Beats

Role: lead

NCT02158559Phase 4Unknown

the Effect of Danhong Injection on Microcirculation in the Treatment of Patients With STEMI After the PTCA Surgery.

Role: lead

NCT02152280Phase 4Unknown

A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke

Role: lead

NCT01863407Phase 3Unknown

Study of Dexamethasone-Allantoin-Metronidazole (DAM) Solution in the Treatment of Post-Operative Ileus (POI)

Role: lead

All 7 trials loaded